Join us for an informative session showcasing how King’s College London researchers can collaborate with Apollo Therapeutics, a leading portfolio biopharmaceutical company dedicated to advancing academic discoveries into transformative new medicines.

Background

Apollo was initially founded in 2016 as a drug discovery fund by Imperial, UCL and Cambridge; together with GSK, AstraZeneca and Johnson & Johnson. The aim then, as now, was to create innovative new medicines by matching breakthroughs in basic medical research made at the universities with industrial drug discovery expertise at Apollo Therapeutics.

After a series of significant fundraising rounds, exceeding $450m, Apollo was established as a portfolio pharma company. King's College London and the Institute of Cancer Research joined a few years later, followed by Oxford University in 2024. Apollo now has six programmes in the clinic, and a strong pre-clinical pipeline.

Why collaborate with Apollo?

• Engage from the earliest stages: Apollo partners long before patents are filed or formal therapeutic development begins, supporting projects all the way to the clinic
• Benefit from pre‑agreed collaboration terms: with contracting and financial frameworks already in place, projects can progress quickly without lengthy negotiations
• Access flexible funding models: support ranges from milestone‑based pre‑clinical proof‑of‑concept studies to multi‑million‑pound pre‑clinical and clinical programmes

If you have any questions about this event, please reach out to King's Innovation Catalyst at innovation@kcl.ac.uk.